Ralph A. Schmid
Bern, BE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.
Journal: EMBO molecular medicine
Published: December 11, 2025
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.
Journal: EMBO molecular medicine
Published: March 06, 2025
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 15, 2024
Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer.
Journal: Cell death and differentiation
Published: January 17, 2024
Second Primary Cancer Among Patients With Papillary Thyroid Carcinoma Following the Chernobyl Disaster.
Journal: JAMA network open
Published: August 17, 2023
Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Journal: International journal of molecular sciences
Published: August 30, 2022
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.
Journal: Cell death discovery
Published: August 23, 2022
The development of machine learning in lung surgery: A narrative review.
Journal: Frontiers in surgery
Published: April 07, 2022
Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients.
Journal: JTO clinical and research reports
Published: April 05, 2022
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: March 18, 2022
Last Updated: 09/26/2026